GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Impedimed Ltd (ASX:IPD) » Definitions » 5-Year EBITDA Growth Rate

Impedimed (ASX:IPD) 5-Year EBITDA Growth Rate : 31.80% (As of Dec. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Impedimed 5-Year EBITDA Growth Rate?

Impedimed's EBITDA per Share for the six months ended in Dec. 2024 was A$-0.01.

During the past 3 years, the average EBITDA Per Share Growth Rate was 15.10% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 31.80% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 18.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Impedimed was 45.00% per year. The lowest was -28.20% per year. And the median was 16.65% per year.

Competitive Comparison of Impedimed's 5-Year EBITDA Growth Rate

For the Medical Devices subindustry, Impedimed's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Impedimed's 5-Year EBITDA Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Impedimed's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Impedimed's 5-Year EBITDA Growth Rate falls into.


;
;

Impedimed 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Impedimed  (ASX:IPD) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Impedimed 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Impedimed's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Impedimed Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Impedimed Ltd (ASX:IPD) » Definitions » 5-Year EBITDA Growth Rate
Comparable Companies
ASX:COV ASX:CMP ASX:SOM ASX:MX1 ASX:CVB ASX:CSX ASX:EYE ASX:NTI ASX:CDX ASX:LDX ABT BSX SYK MDT XTER:SHL EW SZSE:300760 DXCM XAMS:PHIA STE
Traded in Other Exchanges
IPDQF:USA
Address
50 Parker Court, Unit 1, Pinkenba, QLD, AUS, 4008
Website
https://www.impedimed.com
Impedimed Ltd, together with its subsidiaries, operates in the medical devices space. The company is based in Australia and operates globally, and it generates the majority of its revenue in North America. It is engaged in developing, manufacturing, and distributing noninvasive medical devices. The company offers products that are typically used to assess and monitor lymphedema and heart failure, as well as to measure the tissue composition and fluid status of the patients. The company also offers a cloud-based digital platform (branded as SOZO) to manage patient data. The company recognizes revenue from the stand-alone sale of Legacy Devices and Consumables, the Sale of SOZO Devices, and Software Subscription Services.

Impedimed Headlines

No Headlines